Showing results (41-50 of 253) with videos related to
Sort By:
Pageof 26
Cancer Medicine|April 16, 2019
Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factorsPeter Georgantopoulos, Huiying Yang, LeAnn B Norris, et al.Oncology (Williston Park, N.Y.)|December 15, 2007
Dermatologic challenges in cancer patients and survivorsRania Agha, Karen Kinahan, Charles L Bennett, et al.The Lancet. Psychiatry|May 26, 2023
Increasing overdose deaths among Black Americans: a review of the literatureJason B Gibbons, Samantha J Harris, Keisha T Solomon, et al.Substance Use & Misuse|June 16, 2026
Comparing Buprenorphine Treatment Outcomes Among Kentucky Medicaid Patients by Prescriber Specialty and TypeVictoria R Green, Sachini Bandara, Olivia K Sugarman, et al.Cancer Treatment and Research|November 30, 2022
Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug ReactionsMatthew A Taylor, Ashley C Godwin, Shamia Hoque, et al.Drug, Healthcare and Patient Safety|June 25, 2011
Beyond the black box: drug- and device-associated hypersensitivity eventsCharles L Bennett, Olatokunbo S Adegboro, Elizabeth A Calhoun, et al.Best Practice & Research. Clinical Haematology|March 29, 2005
Clinical characteristics of erythropoietin-associated pure red cell aplasiaKenneth R Carson, Andrew M Evens, Charles L Bennett, et al.Cancer Treatment and Research|November 30, 2022
Fluoroquinolone-Associated Disability and Other Fluoroquinolone-Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent YearsCharles L Bennett, Oscar Champigneulle, Andrew Bennett, et al.Cancer Treatment and Research|November 30, 2022
Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in CopenhagenCharles L Bennett, Bartlett Witherspoon, Kenneth R Carson, et al.Expert Opinion on Drug Safety|June 9, 2016
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting systemDennis W Raisch, John A Rafi, Cheng Chen, et al.Pageof 26